Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?
Wong
Christopher F
CF
Department of Nephrology, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK. chriswong@doctors.org.uk
D019268:Antibodies, Antineutrophil Cytoplasmic / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000378:metabolism; D002986:Clinical Trials as Topic; D003593:Cytoplasm / Q000378:metabolism*; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D008954:Models, Biological; D009504:Neutrophils / Q000276:immunology*; D000069283:Rituximab; D014657:Vasculitis / Q000188:drug therapy*
D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab